Rituximab, Vincristine, Cyclophosphamide, Methotrexate, Doxorubicin, Cytarabine Combination

This is a multi-drug chemotherapy and immunotherapy regimen combining rituximab, vincristine, cyclophosphamide, methotrexate, doxorubicin, and cytarabine. Note that the input query included "cytarabine" twice, which appears to be a duplication in the query string rather than indicating two distinct components or dosages of cytarabine. Based on the search results summary, this combination or variations of it are primarily used for treating various types of lymphoma, including diffuse large B-cell lymphoma (DLBCL), intravascular large B-cell lymphoma (IVLBCL), and other B-cell non-Hodgkin lymphomas. The specific combination doesn't have a standard acronym like R-CHOP but incorporates elements from established regimens. It is sometimes used in CNS-oriented therapy, particularly when high-dose methotrexate and intrathecal chemotherapy are involved. Clinical trials have indicated efficacy for variations of this combination in high-risk lymphomas, reporting promising survival rates. Each drug plays a specific role: * **Rituximab:** A monoclonal antibody targeting the CD20 protein on B cells. * **Vincristine:** A chemotherapy drug that disrupts cell division by inhibiting microtubule formation. * **Cyclophosphamide:** An alkylating agent that damages DNA. * **Methotrexate:** An antimetabolite that interferes with DNA synthesis. * **Doxorubicin:** An anthracycline antibiotic that inhibits DNA and RNA synthesis. * **Cytarabine:** A nucleoside analog that interferes with DNA synthesis. The regimen is administered in cycles with specific dosing schedules. Common side effects reported include neutropenia, leucocytopenia, and other hematological toxicities.